ArticleAlzheimer's & dementia (New York, N. Y.)

Bayesian meta-analysis of phase 3 results of aducanumab, lecanemab, donanemab, and high-dose gantenerumab in prodromal and mild Alzheimer's disease.

Stefan J Teipel et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.